Biotin-ligand complexes with sreptavidin quantum dots for in vivo cell labeling of membrane receptors by Lidke, Diane S. et al.
1/18 
 
 
 
 
Biotin-Ligand Complexes with Streptavidin Quantum Dots for in vivo Cell Labeling of 
Membrane Receptors 
 
 
 
Diane S. Lidke1, Peter Nagy2, Thomas M. Jovin1, Donna J. Arndt-Jovin1* 
 
 
 
1Department of Molecular Biology, Max Planck Institute for Biophysical Chemistry, 37077 
Goettingen, Germany   
2Current address: Department of Biophysics and Cell Biology, Medical and Health Science 
Center University of Debrecen, 4012 Debrecen Hungary 
 
Running title:  Ligand-Quantum Dot complexes  
 
 
* To whom correspondence should be addressed. 
   E-mail: djovin@gwdg.de 
   Phone: 49(0)551-2011393  FAX: 49(0)551-2011467 
 
 
Submitted for: 
“Quantum Dots in Biology”, ed. M. Bruchez (Humana Press, Totowa, NJ, 2005) 
 
2/18 
 
Summary 
The unique fluorescence properties of quantum dots (QDs), particulary high brightness and 
photostability, make them ideal probes for tracking proteins in live cells using real-time 
visualization.  We have shown that QDs conjugated to Epidermal Growth Factor (EGF) act as 
functional ligands for their receptor, erbB1.  Here, we describe protocols for (a) conjugation of 
streptavidin-QDs to biotinylated ligand, (b) formation of ligand-QD-receptor complexes and (c) 
quantification of binding and internalization of receptor complex using both high-resolution 
fluorescence microscopy and flow cytometry.   
 
Keywords: epidermal growth factor, EGF, epidermal growth factor receptor, EGFR, erbB1, 
endocytosis, biotin, streptavidin 
 
1.   Introduction 
The erbB family of receptor tyrosine kinases (RTK) includes erbB1 (the classical epidermal 
growth factor receptor, EGFR), erbB2, erbB3 and erbB4 (1). Binding of EGF to the extracellular 
domain of erbB1 leads to auto- and transactivation of cytoplasmic protein kinase domains in 
response to the formation (3) or reorientation (4-6) of homo- and heteroassociated RTK 
monomers. This activation of the receptor initiates signaling cascades, which control a variety of 
cellular processes such as DNA replication and division (1,2). ErbB1 activation results in 
clathrin-mediated endocytosis via coated pits, covalent modification of the receptor, and 
endosomal trafficking resulting in both down-regulation through proteosomal degradation and 
recycling to the cell membrane.  The proper function of erbB1 in the cell is critical, given that 
overexpression or mutations of the erbB1 are implicated in many types of cancer (1,7).  
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We have shown that QDs conjugated to EGF act as functional ligands for erbB1, and that 
their unique fluorescence properties provide the means for prolonged real-time visualization of 
the multiple steps in signaling mechanisms in living cells (8).  In this chapter we outline 
procedures for binding biotinylated ligands to commercial streptavidin conjugated quantum dots, 
for specific labeling of growth factor receptors with these ligands and for quantitative 
measurements of the receptor complexes by both fluorescence microscopy and flow cytometry. 
 
2. Materials 
1. Phosphate buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 7.9 mM Na2HPO4, 1.5 nM 
KH2PO4 , pH 7.3.  Autoclave before use and store at room temperature.  PBS/BSA: add 
0.1% BSA just before use. 
2. Tyrode’s buffer without glucose: 135 mM NaCl, 10 mM KCl, 0.4 mM MgCl2, 1 mM 
CaCl2, 10 mM HEPES, pH 7.2 .  Autoclave before use and store at room temperature.  
Tyrode’s plus: add 20 mM glucose and 0.1% BSA just before use. 
3. Streptavidin conjugated Quantum Dots from Quantum Dot Corporation (Hayward, CA, 
www.qdots.com). Hereafter called SAvQD. 
4. LabTek 8-well or 2-well coverslip chambers from Nunc. 
5. Coverslips, acid washed and sterilized. 
6. Cell culture medium appropriate for the particular cell line. Various commercial vendors.  
7. Emission filters for specific QD emission wavelengths, 20 nm FWHM Chroma 
(Brattleboro, VT). 
8. Biotinylated-EGF and EGF from Molecular Probes (Invitrogen, www.probes.com). 
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9. Paraformaldehyde (PFA) fixative. Paraformaldedyde, analytical grade. Freshly prepared 
4% solution in PBS. A 40% solution can be prepared and kept in small aliquots at –20 
°C. Thaw at 50 °C and immediately dilute in PBS before use. 
10.  Tris-saline buffer: 125 mM NaCl, 25 mM Tris-HCl, pH 7.3. 
11.  Trypsin solution for releasing adherent cells from their substrates:  sterile solution of 0.5 
mg/ml trypsin in PBS containing 1 mM EDTA. 
12. Acid wash buffer: 0.5 M NaCl, 0.1 M Glycine-HCl, pH 2.5. 
 
3. Methods 
 
3.1  Protocols for making biotin-ligand linked streptavidin-QDs (SAvQD) 
3.1.1 Ratio of biotinylated ligand to QDots 
 The present formulation of the QDs from Quantum Dot Corporation includes a 
polyethylene glycol 2000 (PEG) outer layer to which 5-10 streptavidin molecules per QD are 
covalently linked.   This allows the stochiometry of the ligand-QD complex to be varied.  It is 
preferable to use monovalent biotinylated ligands where the biotin is conjugated to a single 
known residue or position. In this way the properties of the ligand-QD complex can be better 
controlled and standardized and potential cross-linking of the QDs via the ligand is avoided. By 
mixing SAvQDs, biotinylated ligand and free biotin at different molar ratios, one can create QDs 
with different numbers of attached ligands.  We assume a Poisson distribution.  To create 
primarily monovalent biotin conjugates mix a 10-fold molar excess of SAvQDs with the 
biotinylated ligand. 
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3.1.2 Pre-formed complexes 
1. Dilute SAvQD to 20 nM in PBS/BSA. 
2. Dilute biotinylated ligand to the appropriate desired molarity in PBS/BSA. 
3. Add SAvQDs to ligand and mix with a micropipette. 
4. Incubate at 4 °C for at least 30 min with gentle agitation or rotation. (See Note 1).  
 
3.1.3 Purification of ligand-QD conjugates 
After the ligand-QD complex is formed, unbound ligands that are smaller than the QDs can be 
removed from the conjugate by passing the QDs through a size exclusion column. For SAvQDs 
described above, Sephadex G-25 medium grade gel filtration is recommended; the SAvQDs will 
elute in the void volume. Use a 1: 20 ratio of sample to column volume for good separation.  
Spin columns can be used for sample volumes of 50 µl or less.  
1. Swell and pour the Sephadex according to the manufacturer’s instructions.  
2. Equilibrate the column in PBS by washing with at least 3 column volumes.  
3. Allow the buffer to just enter the top of the gel bed before adding the sample. Avoid air 
bubbles.  
4. Add the sample to the top of the gel bed, allow the sample to enter the gel and add PBS to 
elute the sample.   
5. Collect the fractions containing the QDs. 
 
3.2 In vivo, in situ labeling of cells with ligand-QD conjugates for fluorescence microscopic 
imaging 
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3.2.1 Plating cells 
Coverslips and coverslip chambers 
Logarithmically growing cells are replated in complete culture medium at the appropriate 
densities one or two days prior to the experiment. In the case of experiments with growth factor 
receptors, the cells are serum-starved for 16 - 24 h prior to the experiment to reduce signaling 
induced by the serum in the medium. 
 
3.2.2 Labeling cell surface receptors with preformed ligand-QD complex  
 
1. Wash cells once with Tyrode’s plus and maintain in this buffer for the experiment.  
2. Place the coverslip chamber on the microscope stage and equilibrate to the desired 
temperature.  
3. Dilute the ligand-SAvQD complex (in this case EGF-QD) to twice the final concentration 
in Tyrode’s plus. (See Note 2.) 
4. Add an equal volume of EGF-QD in Tyrode’s plus to the cells in the well under 
observation to a final concentration of 5 - 200 pM. 
5. Start imaging. 
  
3.2.3 Labeling cell surface receptors in a two-step procedure  
In some situations the preformed complex may not be functional or the system may not 
respond properly with the preformed complex due to (a) steric hindrance by the SAvQD during 
ligand binding or (b) SAvQD inhibition of a conformational change of the ligand required for 
binding. In addition, ligands with multiple biotins can cause aggregation of SAvQDs. Thus, if 
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one does not see binding with the preformed complex or observes aggregation of SAvQDs in the 
one-step protocol, the following two-step protocol may be useful. We have successfully used this 
procedure with both the EGF and the transferrin receptors (8,9).  
 
1. Wash cells once with ice cold Tyrode’s plus and keep in this buffer for the experiment. 
Put cells on ice.  
2. Incubate cells with biotinylated-ligand (in this case 1 nM biotin-EGF, see Note 3) for 5-
10 min. 
3. Wash with ice cold Tyrode’s plus several times. 
4. Add cold 200 pM SAvQD for 5-15 min. 
5. Wash the cells several times with cold Tyrode’s plus. 
6. Place cells on the microscope stage with appropriate temperature control and image. 
7. For snapshots of the behavior of the ligand-QD complex over time, incubate coverslips at 
the appropriate temperatures and times and fix in 4% paraformaldehyde for 15 min on 
ice to prevent redistribution of the QDs.  After fixation, wash the coverslips with Tris-
saline buffer for 10 min several times and mount in PBS for microscopy. 
 
3.2.4 In vivo visualization and quantitation of ligand-QD binding by fluorescence confocal 
microscopy 
Binding plot for ligand-QD to cells expressing a GFP membrane protein (may be the ligand-
binding protein or another membrane protein simply used as a marker). 
 
1. Grow cells in 8-well LabTek chambers as described above. 
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2. Wash cells once with Tyrode’s plus and keep in 200-250 µL of Tyrode’s plus for 
imaging. 
3. Begin acquisition of a time series with single or multiple focal planes. 
a. Typically, a 63× or 40× 1.2 NA water immersion objective is recommended.  
Simultaneous excitation of GFP and QD605 can be achieved at 488 nm.  An 
imaging system with two detectors, e.g. Zeiss LSM510-META, allows the 
simultaneous collection of GFP and QD signals with appropriate filters (in this 
case, 520/20 bandpass and 585 longpass, respectively). 
4. After several time points are acquired, add the pre-formed EGF-QD complexes to the 
buffer (1:1 dilution) without disrupting the time series. 
5. Analysis (8) 
a. Background subtraction from both channels is performed. 
b. The membrane region of the cell is segmented by a global threshold in the green 
channel and the mask is dilated according to a pixel width corresponding to the 
membrane circumference.  
c. The average QD intensity (from the red channel) in the membrane mask is plotted 
over time (See Figure 1). 
 
3.2.5  Two-color QD “chase” experiment 
Multicolor EGF-QDs may be used to track endocytosis of the receptor-ligand complex and to 
follow subsequent steps in time.  Two different colors of ligand-QDs are delivered sequentially. 
(An example of this data may be found in a color image included only on the CD ROM copy of 
this chapter, Figure S1) 
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1. The day before the experiment, plate cells on coverslips if taking fixed cell time points or 
in Lab-Tek coverslip chambers for live cell imaging. 
2. Prepare two batches of QD-ligand as above, with separated emission spectra, such as 
SAvQD525 and SAvQD605. 
3. Wash the cells in Tyrode’s plus buffer and keep in this buffer. 
4. Incubate the cells in a non-saturating concentration (<200 pM in the case of EGF-QD) of 
the first QD-ligand (QD605) for 5 – 10 min at 37 °C while taking time-lapse images on a 
confocal microscope or incubate coverslips in a moist chamber for samples to 
subsequently fix.  
5. Wash away excess QD-ligand by two changes of Tyrode’s plus. 
6. Incubate at 37 °C for at least 5 min to clear the membrane of ligand-QD (image in vivo). 
7. Add 1 nM of ligand of another color, EGF-QD (QD525), and incubate at 37 °C for 
desired time in vivo with imaging or for desired fixed time points. 
8. For fixed samples, wash coverslips in Tyrode’s buffer and fix at 4 °C for 15 min in 4% 
PFA (see section 3.2.3).  
9. Wash with cold Tris–saline several times. 
10. Antibody staining for activated erbB1, endocytic markers or other cell components can 
be carried out at this point. 
11. Mount coverslips onto a drop of PBS on a microscope slide, seal with nail polish. Image 
in fluorescence microscope using appropriate filters. 
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3.3 Quantitative measurement of EGF-QD binding and internalization using flow 
cytometry 
Many properties of quantum dots, including their brightness and extreme photostability, make 
them very valuable for time-lapse fluorescence microscopy.  However, a QD-labeled ligand or 
antibody is increased in size by 10-20 nm per bound QD.  Therefore, carefully planned control 
experiments are necessary to establish that the QD does not interfere with the normal biological 
function of the ligand or antibody. Flow cytometry is an indispensable method for quantitation of 
binding and internalization data with high statistical precision. The following protocol can be 
used to show specific and saturable binding of EGF-QD to erbB1 on the cell surface, and 
demonstrate its uncompromised biological activity by monitoring internalization of the acceptor-
ligand complex. 
 
3.3.1 EGF-QD specifically binds to a saturable binding site in the membrane of erbB1-
expressing cells 
1. Prepare preformed EGF-QD at a ratio of 1:1 as described in section 3.1.2 - 3.1.3. 
2. Trypsinize A431 cells and resuspended in PBS/BSA at a density of 5 ·106/mL, and store 
on ice (see Note 4). 
3. Prepare a 2-fold dilution series of EGF-QDs. 1000 µL of the highest concentration of 
EGF-QD (100 nM) in PBS/BSA in a flow cytometry tube (see Note 5). Thorough mixing 
is very important. The tubes are kept on ice during the entire labeling procedure. 500 µL 
is pipetted from this solution to another tube to which 500 µL of PBS/BSA is added 
yielding the second highest concentration (50 nM) of EGF-QD. This procedure is 
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repeated until the lowest concentration is reached. The result is a dilution series of tubes 
filled with 500 µL of different concentrations of the ligand on ice (see Note 6). 
4. Add 20 µL of the cell suspension to each ligand solution and mix thoroughly (see Note 
7). Incubate the cells on ice for 60 min with regular mixing. 
5. Measure the samples on a flow cytometer without washing (see Note 8). An unlabeled 
cell sample is also included in the measurement, the fluorescence intensity of which is 
subtracted from the mean fluorescence intensities of each sample. The corrected 
fluorescence intensities are plotted as a function of ligand concentration, and the 
characteristics of ligand binding are analyzed. 
 
3.3.2 Binding of streptavidin-coated quantum dots to cells labeled with different molar 
ratios of EGF and biotin-EGF 
Results of the previous experiments showed that EGF-QD binds to a saturable binding site on the 
surface of A431 cells. Strong evidence for specific binding is provided by competitive inhibition 
by another ligand. Activation of erbB1 requires the binding of two EGF molecules to a dimer of 
erbB1 receptor (3, 10). The relatively large size of quantum dots requires one to show 
unambiguously that the ligand-QD is functional. Furthermore, if erbB1 molecules are at high 
density on the cell surface of A431 cells, a bound quantum dot may sterically hinder binding to a 
neighboring receptor. To rule out size or steric hindrance by the QDs, we labeled cells with 
different molar ratios of EGF and biotinylated-EGF, followed by SAvQD and determined 
whether the fluorescence intensities of the samples were linearly proportional to the molar 
fraction of biotin-EGF. The higher the molar fraction of biotinylated-EGF, the higher the 
probability of finding two biotinylated-EGF molecules close to each other, e.g. binding to two 
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erbB1 proteins in a dimer. This would result in leveling off of the fluorescence intensity curve at 
high biotin-EGF concentrations. The fact that we found a strictly linear relationship implies that 
binding of streptavidin-coated quantum dots is not sterically limited (Fig. 2). 
1.  Trypsinize A431 cells and resuspend in PBS/BSA at a density of 2 ·106/mL. Store on ice 
(see Note 4). 
2. Prepare 100 nM stock solutions of biotin-EGF and EGF in PBS/BSA. Keep the solutions 
on ice. 
3. Prepare a 20 nM stock solution of SAvQD in PBS/BSA and store on ice. 
4. Prepare a series of samples (total volume of each is 50 µL) in which the molar ratio of 
biotin-EGF changes from 0 to 100 %, e.g. 0, 12.5, 25, 37.5, 50, 62.5, 75, 87.5, 100%). 
The total concentration of EGF (biotinylated+non-biotinylated) is 100 nM in each 
sample. 
5. Add 50 µL of cell suspension to each tube and mix thoroughly. Incubate the samples on 
ice for 30 min with regular shaking. 
6. Layer 1 mL of fetal calf serum under the cell suspension and centrifuge the cells at 4 oC. 
Discarde the supernatant. 
7. Add 300 µl of the 20 nM quantum dot solution to each pellet and incubate the samples on 
ice for 30 min with regular shaking (see Note 9). 
8. Without washing, measure the sample intensities using a flow cytometer. 
 
3.3.3 Quantitative measurement of EGF-QD internalization 
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Although microscopy experiments can measure the internalization of ligand-QD in a  qualitative 
or semi-quantitative manner with subcellular resolution, flow cytometry is indispensable for 
obtaining a quantitative description of the process. 
1. Couple Biotin-EGF to SAvQDs at a molar ratio of 6:1 as described in section 3.1.2. 
2. Trypsinize A431 cells and resuspended at a density of 106/mL in Tyrode’s buffer plus. 
3. Add 1 nM EGF-QD to the sample and incubate at 37 oC with regular shaking. 
4. Take 600 µL samples at 0, 5, 10, 20 and 30 min.  
5. Add 5 mL of acid wash buffer to half of the sample, and incubate on ice for 5 min. 
6. Wash with a large excess of PBS and resuspend cells in 300 µL Tyrode’s plus.   
7. Measure the fluorescence intensities of the acid washed sample and the non-acid-treated 
sample by flow cytometry to obtain the fraction of internalized ligand. (See Note 10). 
 
4. Notes 
1. Thoroughly mix the SAvQDs and ligands by pipetting up and down several times.  Mix 
in equal volumes so that the stoichiometry does not vary throughout the solution at the 
time of mixing.  
 
2. Dilute the ligand-SAvQD complex from PBS into Tyrode’s plus just before use since the 
SAvQDs aggregate with time in buffers containing divalent cations. 
 
3. In performing similar experiments on another system than the EGFR, the researcher 
should adjust the concentration of ligand and incubation times according to the binding 
constant of the receptor or protein- ligand interaction. 
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4. The cell membrane is in a constant state of recycling. Antibodies and ligands typically 
induce the internalization of their receptor, and newly synthesized receptors continuously 
reach the plasma membrane by exocytosis. If cells are labeled at a temperature 
permissive to endo- and exocytosis, cells engulf EGF-QD receptors, and the freshly 
exocytosed receptors will also bind EGF-QD due to the continued presence of the label in 
the extracellular space. This results in a higher level of EGF-QD binding than what 
would be expected based on the original number of receptors on the cell surface, giving 
rise to binding that is difficult to saturate. Therefore, both the cell suspension and the 
ligand dilution series are kept on ice during the whole duration of the experiment, and all 
solutions are prepared in flow cytometry tubes to minimize the number of times a 
solution has to be transferred from one tube to another. Although flow cytometers are 
usually not thermostated, if the tubes are kept on ice until measurement, ligand 
internalization is minimized. 
 
5. The amount of receptor-bound ligand is usually negligible compared to the total amount. 
However, if a high affinity ligand is investigated and the labeling volume is minimized, 
the decreased concentration of free ligand in the extracellular space (called ligand 
depletion) cannot be overlooked. E.g. if 105 cells expressing 106 receptors/cell are labeled 
in the presence of 10 nM ligand in a volume of 500 µL, the number of bound ligands is 
105 ⋅ 106=1011 assuming saturation. The total number of added ligands is 10⋅10-9 mole/L ⋅ 
500⋅10-6 L ⋅ 6⋅1023 1/mole=3⋅1012. In this case 33% of the total ligand amount is bound, 
severely distorting the calculations. As a rule of thumb 5% ligand depletion is usually 
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considered negligible. Beyond this limit either the real free ligand concentration has to be 
determined or corrections have to be introduced in the calculation, the details of which 
are beyond the scope of this chapter. 
 
6. The ligand can also be depleted by binding to the wall of the labeling tube which can be 
minimized by carrying out the experiment in the presence of 0.1-0.5% (w/v) BSA. In 
addition, the same number of cells are labeled in identical volumes to ensure similar 
conditions (e.g. a constant number of total binding sites). 
 
7. Dilution of the ligand after adding 20 µL cell suspension to 500 µL ligand solution is 
either neglected or can be corrected for in the following way: ccorr=corig ⋅ 500/520, where 
ccorr and corig are the concentrations of the ligand in the diluted and undiluted solutions, 
respectively. 
 
8. Ligand dissociation starts immediately when the concentration of ligand drops in the 
extracellular solution. Therefore, we suggest that samples not be washed before labeling. 
In the case of high affinity ligands saturating their binding site at a low concentration 
fluorescence of the extracellular ligands is negligible. In addition, flow cytometers are 
equipped with a constant background subtraction algorithm, reliably accounting for the 
contribution of extracellular fluorescence  even in the case of low affinity ligands. 
 
9. The number of erbB1 proteins in 105 labeled A431 cells is 105 · 2·106 = 2·1011 
corresponding to 2·1011 / 6·1023 / 300 µL = 1.1 nM mean receptor concentration. The 
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concentration of QD was chosen to be 20 nM to ensure a ~20-fold excess of unbound 
QDs. 
 
10. Since acid washing removes non-covalently-bound molecules from the cell surface, the 
fluorescence intensity of acid-washed samples will represent the internalized pool of QD-
labeled ligands. 
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Figure Legends 
 
Figure 1.  Quantitation of EGF-QDs binding to Chinese Hamster Ovary cells expressing 
erbB1-eGFP.  Plot shows the change in QD intensity inside the membrane mask over time. The 
binding of the EGF-QDs to the cell surface follows and exponential course.   
 
Figure 2.  Binding of SAvQDs to cells labeled with different molar ratios of biotinylated- 
and non-biotinylated-EGF 
A431 cells were incubated in the presence of different molar ratios of biotin-EGF and EGF for 
60 min followed by labeling with SAvQDs. The fluorescence intensity of the samples (empty 
circles) was measured using flow cytometry. The correlation coefficient of a linear fit to the data 
(straight line) was R=0.99. Originally published in (8). 
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QDots track endosomal compartments and vesicular fusion
Pulse chase experiments with two different QD-EGFs
. 
2 hr later, although all vesicles  
show red and green signals, 
clear differences in QD 
populations are seen in the
content of late endosomes and 
lysosomes.
QD605-EGF bound to  ErbB1 
(A431 cells), incubated RT for 3 
min, washed, 5 min 370 C
- add QD525-EGF 8 min 370 C  
Early endosomes red only,  
QD525-EGF predominantly 
external.
Washed and observed 20 
min later at  370 C.
Several different classes 
of endosomes containing 
red only, green only or both 
QD colors (see inset). 
Early, sorting and late 
endosomes are loaded.
